This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An author's correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snydman, D. R.
Right arrow Articles by Gorbach, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snydman, D. R.
Right arrow Articles by Gorbach, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2002, p. 3276-3279, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3276-3279.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms

D. R. Snydman,1,3* N. V. Jacobus,1 L. A. McDermott,1 R. Ruthazer,1,3 E. Goldstein,4 S. Finegold,5 L. Harrell,6 D. W. Hecht,7 S. Jenkins,8,9 C. Pierson,10 R. Venezia,11 J. Rihs,12 and S. L. Gorbach1,2

Departments of Medicine,1 Community Health,2 Clinical Research, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts,3 R. M. Alden Research Laboratories, UCLA Medical Center, Santa Monica,4 Wadsworth Veterans Administration Hospital, Los Angeles, California,5 Duke University Medical Center, Durham,6 Carolinas Medical Center, Charlotte, North Carolina,8 Loyola University Medical Center, Maywood, Illinois,7 Mt. Sinai Medical Center, New York,9 Albany Medical Center, Albany, New York,11 University of Michigan Medical Center, Ann Arbor, Michigan,10 Pittsburgh Veterans Administration Medical Center, Pittsburgh, Pennsylvania,12

Received 8 January 2002/ Returned for modification 24 April 2002/ Accepted 19 July 2002

The activities of BMS-284576, clinafloxacin, moxifloxacin, sitafloxacin, trovafloxacin, imipenem, cefoxitin, and clindamycin against 589 Bacteroides fragilis group isolates were determined. The activity of BMS-284576 was comparable to that of trovafloxacin. Sitafloxacin and clinafloxacin were the most active quinolones, and moxifloxacin was the least active. B. fragilis was the most susceptible of the species, and Bacteroides vulgatus was the most resistant. Association of specific antibiotic resistance with Bacteroides species was noted for all quinolones.

* Corresponding author. Mailing address: Divisions of Geographic Medicine and Infectious Diseases, New England Medical Center, 750 Washington St., Box 238, Boston, MA 02111. Phone: (617) 636-5788. Fax: (617) 636-8525. E-mail: dsnydman{at}lifespan.org.

Antimicrobial Agents and Chemotherapy, October 2002, p. 3276-3279, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3276-3279.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Snydman, D. R., Jacobus, N. V., McDermott, L. A. (2008). In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group. Antimicrob. Agents Chemother. 52: 4492-4496 [Abstract] [Full Text]  
  • Wexler, H. M. (2007). Bacteroides: the Good, the Bad, and the Nitty-Gritty. Clin. Microbiol. Rev. 20: 593-621 [Abstract] [Full Text]  
  • Tanaka, K., Mikamo, H., Nakao, K., Watanabe, K. (2006). In Vitro Antianaerobic Activity of DX-619, a New Des-Fluoro(6) Quinolone. Antimicrob. Agents Chemother. 50: 3908-3913 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Warren, Y. A., Tyrrell, K. L., Merriam, C. V., Fernandez, H. (2006). In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections. Antimicrob. Agents Chemother. 50: 148-155 [Abstract] [Full Text]  
  • Edmiston, C. E. Jr, Krepel, C. J., Kehl, K. S., Seabrook, G. R., Somberg, L. B., Almassi, G. H., Smith, T. L., Loehrl, T. A., Brown, K. R., Lewis, B. D., Towne, J. B. (2005). Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 56: 872-878 [Abstract] [Full Text]  
  • Schaumann, R., Goldstein, E. J., Forberg, J., Rodloff, A. C (2005). Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54: 749-753 [Abstract] [Full Text]  
  • Snydman, D. R., Jacobus, N. V., McDermott, L. A. (2005). Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. J Antimicrob Chemother 55: 1024-1028 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Sprandel, K. A., Rodvold, K. A., Rotschafer, J. C. (2005). Levofloxacin plus Metronidazole Administered Once Daily versus Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 49: 685-689 [Abstract] [Full Text]  
  • Edmiston, C. E., Krepel, C. J., Seabrook, G. R., Somberg, L. R., Nakeeb, A., Cambria, R. A., Towne, J. B. (2004). In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot Infections. Antimicrob. Agents Chemother. 48: 1012-1016 [Abstract] [Full Text]  
  • Jacobus, N. V., McDermott, L. A., Ruthazer, R., Snydman, D. R. (2004). In Vitro Activities of Tigecycline against the Bacteroides fragilis Group. Antimicrob. Agents Chemother. 48: 1034-1036 [Abstract] [Full Text]  
  • Schaumann, R., Blatz, R., Beer, J., Ackermann, G., Rodloff, A. C. (2004). Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 53: 318-324 [Abstract] [Full Text]  
  • Ricci, V., Piddock, L. (2003). Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J Antimicrob Chemother 52: 605-609 [Abstract] [Full Text]  
  • Peterson, M. L., Rotschafer, J. C., Piddock, L. J. V. (2003). Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J Antimicrob Chemother 52: 481-484 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»